



Atty. Dkt. No. 078883/0119

4632
#28
10/17/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christopher Robert BEBBINGTON et al.
Title: RETROVIRAL VECTORS COMPRISING A FUNCTIONAL SPLICE
DONOR SITE AND A FUNCTIONAL SPLICE ACCEPTOR SITE
Appl. No.: 09/508,516
Filing Date: 06/08/2000
Examiner: M. Wilson
Art Unit: 1632

RECEIVED

DEC 16 2002

TECH CENTER 1600/2000

SUPPLEMENTAL AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a response to the Office Communication mailed on October 22, 2002, in connection with the captioned application. By the attached petition for an extension of time and check for the requisite fee, Applicants have extended the date for response to December 22, 2002.

In the Office Communication, the Examiner stated that the reply filed on August 23, 2002 was not fully responsive to the prior Office Action because it did not identify where support for the claim amendments can be found in the disclosure. Accordingly, Applicants submit the following table, which shows where support for each amendment exists in the specification.

Claim	Support in the Specification
1	Page 25, lines 4-8; page 29, lines 15-19; Example 2, page 75, lines 12-30; Figure 6, legend, paragraph bridging pages 68-69.
5	Dependancy has changed.

6	Paragraph bridging pages 32-33, which states that the expression product of the first NOI can be a selectable marker; page 33, lines 23-25, 28-29, which states that the first NOI can also contain both non-coding retroviral elements (such as the retroviral packaging site) and essential retroviral elements (such as the envelope protein).
9	Page 30, lines 20 and 24.
10	Page 30, line 22.
14	Page 25, lines 24-26; page 75, lines 20-21.
15	Page 25, lines 28-30; page 26, lines 1-6.
17	Page 26, lines 1-6.
21	Page 26, lines 18-20; page 39, lines 20-23.
24	Example 2, pages 73-77, specifically page 76, lines 1-14 and Figure 12A.
46	Page 25, lines 9-12, 28-30; Example 2, pages 73-77, Figures 14 and 17.
47	Example 2, page 75, lines 12-30; Figure 6, legend, paragraph bridging pages 68-69; Figures 7-9.
48	Figure 12; page 76, lines 1-14.
49	Page 33, lines 23-26, 28-29 (<i>env</i> gene); page 44, lines 1-13 (where preferential expression of the first NOI is in the primary target cell); Figures 17 and 27C.
50	Paragraph bridging pages 32-33; Figure 14; paragraph bridging pages 76-77; page 44, lines 5-13; Figures 17 and 27C.
51	Page 43, lines 18-20, page 44, lines 5-13; Figure 12; page 77, lines 1-5.
52	Page 77, lines 1-5; Figure 12.
53	Page 26, lines 18-20; page 39, lines 20-23.
54	Page 26, lines 22-23, page 30 lines 16-18, page 39, lines 20-22; page 39, lines 5-6.

55	Page 30, lines 16-18.
56	Page 33, lines 23-25, 28-29; page 44, lines 5-13; Figures 17 and 27C.
57	Page 44, lines 9-12; page 75, lines 12-30.
58	Figures 12B, 13B, 14C and 17.
59	Page 44, lines 9-12; Example 2, pages 73-77

Applicants regret any inconvenience they may have caused the Examiner, and anticipate that the table will facilitate consideration of the pending claims. If the Examiner believes that an interview would advance the prosecution of this application, he is invited to contact the undersigned by telephone.

If there are any fees due in connection with the filing of this Amendment, please charge the fees to our Deposit Account No. 19-0741. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date: Dec 12, 2002

By Michele M. Simkin

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicants
Registration No. 34,717